Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: A 1-year, double-blind, randomized clinical trial

Giuseppe Derosa, Angela D'Angelo, Elena Fogari, Sibilla Salvadeo, Alessia Gravina, Ilaria Ferrari, Arrigo F G Cicero

Research output: Contribution to journalArticle


Objective: To evaluate the effect on coagulation and fibrinolysis parameters and on non-conventional cardiovascular risk factors of metformin plus nateglinide or glibenclamide in naive type 2 diabetes patients. Patients and Methods: A total of 248 type 2 diabetic patients were enrolled and randomly assigned to receive nateglinide or glibenclamide, and netformin for 12 months. We assessed body mass index (BNH), glycated hemoglobin (HbA17c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma-insulin (FPI), postprandial plasma insulin (PPI), homeostasis model assessment index (HOMA index), lipid profile with lipoprotein (a) [Lp(a)], fibrinogen (Fg), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (t-PA), homocysteine (Hcy), systolic blood pressure (SBP), diastolic blood pressure (DBP). Results: After 9 months of treatment, both tested drug combinations were similarly associated with a significant reduction in FPG (nateglinide, -17.2%; glibenclamide, -16.9%, both p1c (-17.3%, p1c (-21%, p1c, (41%, p1c, difference value from baseline observed in the nateglinide-treated group was significantly higher than that observed in the glibenclamide group. Therefore the nateglinide-treated patients showed a significant reduction in some prothrombotic parameters (PAI-1=49%, Lp(a)=-31%, and Hcy=-32.3%, all p

Original languageEnglish
Pages (from-to)1837-1846
Number of pages10
JournalInternal Medicine
Issue number22
Publication statusPublished - Nov 16 2007



  • Glibenclamide
  • Metformin
  • Nateglinide
  • Prothrombotic parameters

ASJC Scopus subject areas

  • Internal Medicine

Cite this